Stock SplitsBy The Online Investor Staff, updated Fri., May. 24, 8:02 AM
|This Slide: #6 of 25|
Slide #6. DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) — 1 for 10 Reverse Split
1 for 10
DelMar Pharmaceuticals is a clinical stage company with a focus on the development of drugs for the treatment of cancer. Co.'s primary product candidate, VAL-083, is a small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of any approved product, or in development for the treatment of cancer. VAL-083 is approved as a chemotherapy in China for the treatment of chronic myelogenous leukemia and lung cancer. Co. is developing VAL-083, a DNA-targeting agent, for the treatment of glioblastoma multiforme and potentially other solid tumors, including ovarian cancer.
DMPI Detailed Information Page & Split History »